Pharmacotherapy of amnestic mild cognitive impairment: lessons from the Memory Impairment Study

Author: Gauthier, Serge

Source: Aging Health, Volume 1, Number 1, August 2005 , pp. 37-38(2)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

<bold>Evaluation of: Petersen RC, Thomas RG, Grundman M et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379–2388 (2005).</bold> A 3-year randomized controlled study comparing donepezil with tocopherol and placebo in 769 subjects with amnestic mild cognitive impairment showed an overall 16% yearly rate of progression to dementia. This was more common in the subjects carrying the apoE4 allele. There was no sustained difference between the treatment groups over the 3 years of treatment. This study design can be used to test new agents that may modify the progression of Alzheimer’s disease.

Keywords: amnestic; donepezil; mild cognitive impairment; tocopherol; treatment

Document Type: Research article

DOI: http://dx.doi.org/10.2217/1745509X.1.1.37

Affiliations: 1: McGill Center for Studies in Aging, 6825 Boul. LaSalle, Verdun, Québec, H4H 1R3, Canada., Email: serge.gauthier@mcgill.ca

Publication date: 2005-08-01

More about this publication?

Aging Health leading coverage of current and emerging topics relating to the safe and effective management of therapy in the elderly, all subject to rigorous peer review. The journal focuses on the most important advances and highlights their relevance in the clinical setting. The journal has been designed to deliver essential concise information in an easily assimilable format - vital for the increasingly time-constrained professional.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites